title: Hemodynamic actions and mechanisms of systemically administered α-MSH analogs in mice.
abstract: α-Melanocyte-stimulating hormone (α-MSH) regulates important physiological functions including energy homeostasis and inflammation. Potent analogs of α-MSH, [Nle(4), D-Phe(7)]-α-MSH (NDP-α-MSH) and melanotan-II (MT-II), are widely used in pharmacological studies, but the hemodynamic effects associated with their systemic administration have not been thoroughly examined. Therefore, we investigated the hemodynamic actions of these compounds in anesthetized and conscious C57Bl/6N mice using peripheral routes of administration. NDP-α-MSH and MT-II induced mild changes in blood pressure and heart rate in anesthetized mice compared to the effects observed in conscious mice, suggesting that anesthesia distorts the hemodynamic actions of α-MSH analogs. In conscious mice, NDP-α-MSH and MT-II increased blood pressure and heart rate in a dose-dependent manner, but the tachycardic effect was more prominent than the pressor effect. Pretreatment with the melanocortin (MC) 3/4 receptor antagonist SHU9119 abolished these hemodynamic effects. Furthermore, the blockade of β(1)-adrenoceptors with metoprolol prevented the pressor effect and partly the tachycardic action of α-MSH analogs, while the ganglionic blocker hexamethonium abrogated completely the difference in heart rate between vehicle and α-MSH treatments. These findings suggest that the pressor effect is primarily caused by augmentation of cardiac sympathetic activity, but the tachycardic effect seems to involve withdrawal of vagal tone in addition to sympathetic activation. In conclusion, the present results indicate that systemic administration of α-MSH analogs elevates blood pressure and heart rate via activation of MC(3/4) receptor pathways. These effects and the consequent increase in cardiac workload should be taken into account when using α-MSH analogs via peripheral routes of administration.
authors.affiliation: Department of Pharmacology, Drug Development and Pharmaceutics, and Turku Center for Disease Modeling, University of Turku, Turku, Finland. pperin@utu.fi
authors.forename: Petteri
authors.initials: P
authors.lastname: Rinne
authors.forename: Sanna
authors.initials: S
authors.lastname: Tikka
authors.forename: Satu
authors.initials: S
authors.lastname: Mäkelä
authors.forename: Tomi
authors.initials: T
authors.lastname: Streng
authors.forename: Eriika
authors.initials: E
authors.lastname: Savontaus
mesh_terms: D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D003243:Consciousness; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects*; D018738:Hexamethonium / Q000494:pharmacology; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology; D008790:Metoprolol / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D044104:Receptor, Melanocortin, Type 3 / Q000037:antagonists & inhibitors / Q000378:metabolism; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors / Q000378:metabolism; D018043:Receptors, Corticotropin / Q000037:antagonists & inhibitors; D000521:alpha-MSH / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000777:Anesthetics; C574273:MC4R protein, mouse; D010456:Peptides, Cyclic; D044104:Receptor, Melanocortin, Type 3; D044105:Receptor, Melanocortin, Type 4; D018043:Receptors, Corticotropin; C079282:melanotan-II; C103272:SHU 9119; D018738:Hexamethonium; D000521:alpha-MSH; C027756:MSH, 4-Nle-7-Phe-alpha-; D009074:Melanocyte-Stimulating Hormones; D008790:Metoprolol